Therapeutic Response

Wild type ALK and Wild type EGFR status confers therapeutic sensitivity to Cisplatin in combination with Pembrolizumab and Pemetrexed in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Keytruda (pembrolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to pembrolizumab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is based on KEYNOTE-189 (NCT02578680), a randomized, multicenter, double-blind, active-controlled trial conducted in 616 patients where the choice of platinum-containing chemotherapy was either carboplatin or cisplatin.